| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Basic Science Investigation |
1 Center for Radiopharmaceutical Science of ETH, PSI and USZ and Department of Chemistry and Applied Biosciences of ETH, Zurich, Switzerland; 2 PET Center, Division of Nuclear Medicine, University of Zurich, Zurich, Switzerland; and 3 Novartis Institutes for Biomedical Research Basel, Novartis Pharma AG, Basel, Switzerland
Correspondence: For correspondence or reprints contact: Simon M. Ametamey, PhD, Center for Radiopharmaceutical Science of ETH, PSI and USZ, ETH-Hönggerberg, D-CHAB IPW HCI H427, Wolfgang-Pauli-Strasse 10, CH-8093 Zurich, Switzerland. E-mail: simon.ametamey{at}pharma.ethz.ch
11C-ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-11C-methyl-oxime), a noncompetitive and highly selective antagonist for the metabotropic glutamate receptor subtype 5 (mGluR5), was evaluated for its potential as a PET agent. Methods: ABP688 was radiolabeled with 11C by reacting 11C-methyl iodide with the sodium salt of desmethyl-ABP688 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime). The affinity of 11C-ABP688 for mGluR5 was determined by Scatchard analysis using rat whole-brain membranes (without cerebellum). Ex vivo autoradiography, biodistribution, and PET studies with 11C-ABP688 were performed on rats, wild-type mice, and mGluR5-knock-out mice. Results: The overall synthesis time was 45–50 min from the end of radionuclide production. 11C-ABP688 was obtained in good radiochemical yield (35% ± 8%, n = 17, decay corrected), and the specific radioactivity was 150 ± 50 GBq/µmol (n = 17) at the end of the synthesis. Scatchard analysis revealed a single high-affinity binding site with a dissociation constant of 1.7 ± 0.2 nmol/L and a maximum number of binding sites of 231 ± 18 fmol/mg of protein. Ex vivo autoradiography in wild-type mice and rats showed a heterogeneous distribution pattern consistent with the known distribution of mGluR5 in the brain, with the highest uptake in hippocampus, striatum, and cortex. Blocking studies by coinjection of 11C-ABP688 and unlabeled 2-methyl-6-(3-methoxyphenyl)ethynyl-pyridine (1 mg/kg), an antagonist for mGluR5, revealed up to 80% specific binding in rat brain. In mGluR5-knock-out mouse brain, a homogeneous and markedly reduced accumulation of 11C-ABP688 was observed. PET studies on rats and mice using a small-animal PET scanner also demonstrated radioactivity uptake in the brain regions known to be rich in mGluR5. In contrast, radioactivity uptake in mGluR5-knock-out mice was fairly uniform, substantiating the specificity of 11C-ABP688 binding to mGluR5. Conclusion: 11C-ABP688 is a selective tracer for imaging mGluR5 in vivo in rodents and may offer a future tool for imaging mGluR5 in humans using PET.
Key Words: metabotropic glutamate receptor subtype 5 • 11C-ABP688 • mGluR5-knock-out mice • biodistribution
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  V. Treyer, J. Streffer, M. T. Wyss, A. Bettio, S. M. Ametamey, U. Fischer, M. Schmidt, F. Gasparini, C. Hock, and A. Buck Evaluation of the Metabotropic Glutamate Receptor Subtype 5 Using PET and 11C-ABP688: Assessment of Methods J. Nucl. Med., July 1, 2007; 48(7): 1207 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Ametamey, V. Treyer, J. Streffer, M. T. Wyss, M. Schmidt, M. Blagoev, S. Hintermann, Y. Auberson, F. Gasparini, U. C. Fischer, et al. Human PET Studies of Metabotropic Glutamate Receptor Subtype 5 with 11C-ABP688 J. Nucl. Med., February 1, 2007; 48(2): 247 - 252. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
